AC Immune S.A. (ACIU)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in CHFTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CHF m | 15 | 0 | 4 | 15 | 27 | 4 | - | - |
| Operating profit | CHF m | -69 | - | ||||||
| Net profit | CHF m | -62 | -73 | -71 | -54 | -51 | -70 | - | -36 |
| EPS reported | CHF | -0.70 | - | ||||||
| Operating cashflow per share | CHF | -0.66 | - | ||||||
| Capex per share | CHF | 0.01 | - | ||||||
| FCF per share | CHF | -0.67 | - | ||||||
| Free cash flow | CHF m | -67 | - | ||||||
| Net debt | CHF m | -91 | - | ||||||
| Book value equity | CHF m | 45 | - | ||||||
| Book value per share | CHF | 0.45 | - | ||||||
| Number of shares | m | 100.75 | - | ||||||
| DPS (TTM paid) | CHF | 0.00 | - |
Financial summary
Financials in CHFTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 5.58 | - | ||||||
| P/S LTM | x | 70.23 | - | ||||||
| P/FCF LTM | x | -3.74 | - | ||||||
| EV/EBITDA LTM | x | -3.37 | - | ||||||
| EV/Sales LTM | x | 63.99 | - | ||||||
| Earnings Yield LTM | % | -28.08% | - | ||||||
| FCF Yield | % | -26.70% | - | ||||||
| Quality | |||||||||
| ROE | % | -156.78% | - | ||||||
| ROIC | % | -1.14% | - | ||||||
| Operating margin | % | -19.27% | - | ||||||
| Gross margin | % | +100.00% | - | ||||||
| FCF/Sales | % | -1875.4% | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -86.92% | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | - | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | - | ||||||
| FCF/Debt | x | -14.74 | - | ||||||
| Net Debt/EBITDA | x | 0.33 | - | ||||||
| EBIT/Net interest | x | -360.54 | - | ||||||
| Net debt/market cap | % | 0.00% | - | ||||||
| Net debt/Equity | x | -2.03 | - | ||||||
| Gross debt/equity | x | 0.10 | - | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
AC Immune S.A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools. Its core mission is addressing neurodegenerative conditions rooted in protein misfolding, both preventatively and therapeutically. Leveraging its proprietary SupraAntigen and Morphomer platforms, the company engineers a range of vaccines, antibodies, and small molecules specifically designed to engage with aberrantly folded proteins implicated across various neurodegenerative disorders. Its pipeline features Crenezumab, a humanized, conformation-specific monoclonal antibody currently undergoing a Phase II clinical prevention trial for Alzheimer's disease (AD). Additionally, AC Immune is advancing ACI-24, an anti-Abeta vaccine candidate, which is in Phase II clinical evaluation for AD and has successfully completed a Phase Ib study for Down syndrome. Other key candidates include ACI-35, an anti-Tau vaccine candidate that has finished Phase Ib clinical assessment, and a Tau-positron emission tomography (PET) imaging tracer, also in Phase II development. Furthermore, the company is engaged in the research and development of small molecule inhibitors to prevent Tau aggregation, targeting AD and various NeuroOrphan indications. Early-stage efforts include discovery and preclinical programs for a spectrum of neurodegenerative diseases, encompassing diagnostic agents aimed at TDP-43, alpha-synuclein, and NLRP3. The company maintains strategic partnerships and licensing agreements with key industry players such as Genentech, Inc., Biogen International GmbH, Janssen Pharmaceuticals, Inc., Life Molecular Imaging SA, Eli Lilly and Company, and WuXi Biologics. Founded in 2003, AC Immune S.A. is headquartered in Lausanne, Switzerland.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
AC Immune S.A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools. Its core mission is addressing neurodegenerative conditions rooted in protein misfolding, both preventatively and therapeutically. Leveraging its proprietary SupraAntigen and Morphomer platforms, the company engineers a range of vaccines, antibodies, and small molecules specifically designed to engage with aberrantly folded proteins implicated across various neurodegenerative disorders. Its pipeline features Crenezumab, a humanized, conformation-specific monoclonal antibody currently undergoing a Phase II clinical prevention trial for Alzheimer's disease (AD). Additionally, AC Immune is advancing ACI-24, an anti-Abeta vaccine candidate, which is in Phase II clinical evaluation for AD and has successfully completed a Phase Ib study for Down syndrome. Other key candidates include ACI-35, an anti-Tau vaccine candidate that has finished Phase Ib clinical assessment, and a Tau-positron emission tomography (PET) imaging tracer, also in Phase II development. Furthermore, the company is engaged in the research and development of small molecule inhibitors to prevent Tau aggregation, targeting AD and various NeuroOrphan indications. Early-stage efforts include discovery and preclinical programs for a spectrum of neurodegenerative diseases, encompassing diagnostic agents aimed at TDP-43, alpha-synuclein, and NLRP3. The company maintains strategic partnerships and licensing agreements with key industry players such as Genentech, Inc., Biogen International GmbH, Janssen Pharmaceuticals, Inc., Life Molecular Imaging SA, Eli Lilly and Company, and WuXi Biologics. Founded in 2003, AC Immune S.A. is headquartered in Lausanne, Switzerland.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free